Q2 FY2026 EarningsQ2 FY2026 results missed GAAP EPS consensus ($0.22 loss vs. $0.1488 expected) but outperformed on a Non-GAAP normalized basis ($0.13 loss vs. $0.1205 expected). Revenue remained at zero, in-line with expectations for this clinical-stage biotech. The primary variance was driven by a $23.9M non-cash charge related to the fair value adjustment of success payment liabilities and contingent consideration. Management extended the cash runway into mid-2027 following $93.3M in capital raises, including a strategic $25M investment from Mayo Clinic.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sana Biotechnology(SANA) the EBIT is -65.42 M (+31.12%), Miss estimate;the EPS is -0.22 (+43.59%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.07B31.12%
-0.04B55.23%
-0.02B24.11%
EPSMiss expectations
-0.2243.59%
-0.148861.86%
-0.071218.27%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf